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Abstract
Weight gain achieved during pulmonary tuberculosis (PTB) treatment is associated with the likelihood of bacteriological
treatment success. It is recognised that weight and body mass index (BMI) characteristics differ between ethnic groups in
health and illness states. However there has been no prior investigation of how ethnic differences in BMI might influence
tuberculosis treatment outcome. Our aim was to investigate predictors of microbiological response to PTB treatment at the
Tuberculosis Clinic in Timika, Papua Province, Indonesia and specifically, to determine the contribution of ethnicity. The
population comprises two distinct ethnic groups - Asian (Non-Papuan) and Melanesian (Papuan). We conducted a
prospective study of adults with smear-positive PTB. Treatment outcomes were 1- and 2-month sputum culture and time to
microscopy conversion. Clinical measures included weight, BMI, chest radiograph, pulmonary function including forced
expiratory volume in 1 second (FEV1) and haemoglobin. One hundred eighty six participants (83 Papuan, 103 non-Papuan
Indonesians) were enrolled. At baseline, Papuans had higher mean weight and BMI than non-Papuans (50.0 kg versus
46.9 kg, p = 0.006 and 20.0 kg/m2 versus 18.7 kg/m2, p = 0.001 respectively). This was despite having lower mean
haemoglobin (11.3 vs 13.1 g/dL, p,0.0001), higher smoking and HIV rates (37% vs 21%, p = 0.02 and 20% vs 5%, p = 0.01
respectively) and longer median illness duration (3 vs 2 months, p = 0.04), but similar radiological severity (proportion with
cavities 55% vs 57%, p = 0.7), sputum smear grade (p = 0.3) and mean % predicted FEV1 (63% vs 64%, p = 0.7). By 2 months,
Papuans had gained still more weight (mean 5.9 vs 4.2 kg, p = 0.02), and were more likely to have negative sputum culture
(49/56 vs 45/67, p = 0.02), in univariable and multivariable analyses controlling for other likely determinants of culture
conversion. In conclusion, Papuans had better early microbiological outcome from PTB treatment, which may relate to
better preservation of weight and greater early weight gain.
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Introduction
Factors which predict response to pulmonary tuberculosis (PTB)
treatment need to be clearly defined and should be taken into
account when interpreting the findings of TB clinical trials.
Interim microbiological measures including 2-month sputum
culture conversion [1,2], time to sputum smear microscopy
conversion [3,4], or time to detection of Mycobacterium tuberculosis
in sputum culture [5,6], can be used to help identify patients at risk
of unsuccessful treatment 6-month outcome, or subsequent
relapse. Since these measures are imperfect, there is active
research into biomarkers which might better indicate an individ-
ual’s response to treatment, and thereby facilitate early endpoints
in trials of comparative regimens [2,7]. In the meantime however,
simple and inexpensive measures can continue to shed light on TB
responses and offer insights into disease pathophysiology, partic-
ularly in high burden under-resourced settings.
Tuberculosis which is more advanced at the time of treatment
initiation is recognised to be reliably associated with delayed
clearance of M. tuberculosis from sputum; thus the presence of
cavitary disease and higher bacillary density in sputum at
tuberculosis diagnosis are best recognised to predict microscopy
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and culture conversion in 2-month sputum samples [5,6,8–11].
Less well understood are the host and organism predictors of
outcome, although studies have variously identified older age
[5,8,9,11], smoking [5,6,9], diabetes [11], male sex [9] and W-
Beijing genotype [6] as predictors of slower microbiological
response.
In addition to these outcome predictors measurable at baseline,
the amount of weight gain achieved by tuberculosis patients during
treatment also appears to be associated with microbiological
response [12,13]. Weight gain of#5% during the first 2 months of
tuberculosis treatment is associated with an increased relapse risk
[12], and those experiencing weight loss or poor weight gain are
more likely to have unsuccessful 6-month outcomes [14–17].
Weight gain is therefore considered an important outcome
measure in clinical trials of nutritional interventions in tuberculosis
[18,19]. There is a bi-directional relationship between malnutri-
tion (which impairs cell-mediated immunity), and tuberculosis
(which further aggravates weight loss) [20]. Weight is universally
measured in TB treatment programs, essentially comprising a free
‘point of care test’, and has been advocated as a simple measure to
predict TB treatment outcome [15].
The World Health Organisation (WHO) describes standard
body mass index (BMI) cut-points to define categories of
nutritional status [21], but these cut-points do not apply equally
well across all ethnic groups [22]. Asian populations generally
require lower [23,24], and Melanesians, higher [25,26] cut-points.
BMI cannot distinguish lean from fat mass and is an imprecise
surrogate for nutritional status, but is the most practical,
inexpensive measure [27].
There is limited evidence pertaining to the influence of ethnicity
on responses to tuberculosis treatment. Such studies are generally
challenging due to the difficulty in comparing outcomes between
different geographical sites. In a population of tuberculosis patients
in eastern Indonesia comprising two distinct ethnic groups - Asian
(Non-Papuan) and Melanesian (Papuan), who have recognisably
different anthropomorphic characteristics, we sought to identify
the predictors of microbiological outcome of PTB treatment, and
determine the contribution of ethnicity.
Materials and Methods
This study was performed as part of a clinical trial of adjunctive
L-arginine and vitamin D for PTB (clinicaltrials.gov/
NCT00677339) [28,29]. In this study, neither intervention
significantly affected the outcome measures [28]. Eligible sequen-
tial study participants with PTB who had no previous history of
treatment were enrolled at the Tuberculosis clinic in Timika,
Papua Province, Indonesia. The TB case notification rate in
Timika has been estimated at 311/100 000 [30]. Inclusion criteria
included age $15 years, sputum smear-positive for acid fast bacilli
(AFB), and provision of written informed consent from the
participant, or guardian if aged ,18. Standard tuberculosis
treatment was administered in a directly observed fashion in fixed-
dose combination (FDC) tablets containing rifampicin 150 mg,
isoniazid 75 mg, pyrazinamide 400 mg and ethambutol 272 mg
for 2 months (30–39 kg: 2 tablets daily; 40–54 kg: 3 tablets daily;
55–70 kg: 4 tablets daily; $71 kg: 5 tablets daily), then rifampicin
and isoniazid for 4 months also in standard weight-adjusted doses
[31]. Local healthy controls were eligible if they were aged $18
years, gave written informed consent, and had no co-morbidities.
Ethics statement
The study was approved by the Human Research Ethics
Committees of Menzies School of Health Research, Darwin,
Australia and the National Institute for Health Research and
Development, Jakarta, Indonesia. All participants provided written
informed consent.
Definitions and procedures
Treatment outcome was categorised as cured, completed, failed,
died, defaulted or transferred out [4], or dichotomised as successful
(cured, completed) or unsuccessful (failed, defaulted, died), as
described elsewhere [14]. Chest radiographs, pulmonary function,
Figure 1. Body mass index at TB diagnosis.
doi:10.1371/journal.pone.0076077.g001
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Table 1. Characteristics of study participants.
Papuans Non-Papuans p value
TUBERCULOSIS PATIENTS AT DIAGNOSIS: Number 83 103
Age in years: median (range) 26 (21–35) 30 (24–38) 0.005
Female: no. (%) 26 (31%) 33 (34%) 0.7
HIV positive: no./no.tested (%) 14/70 (20%) 4/74 (5%) 0.01
Current smoker: no. (%) 31 (37%) 22 (21%) 0.02
Height (m): mean (SD) 1.58 (0.71) 1.58 (0.08) 0.8
Weight (kg): mean (SD)
All 50.0 (6.9) 46.9 (7.9) 0.006
Female 44.4 (6.8) 42.5 (8.7) 0.4
Male 52.5 (5.3) 49.2 (6.5) 0.002
Body mass index (kg/m2): mean (SD)
All 20.0 (2.4) 18.7 (2.8) 0.001
Female 19.1 (3.1) 18.7 (3.8) 0.6
Male 20.4 (1.7) 18.7 (2.2) ,0.0001
Fixed-dose combination recommended starting dose: no. (%)
2 tablets (30–39 kg) 6 (7%) 17 (17%) 0.09
3 tablets (40–54 kg) 57 (69%) 69 (67%)
4 tablets (55–70 kg) 20 (24%) 16 (16%)
5 tablets ($71 kg) 0 (0%) 1 (1%)
Illness duration (months): median (IQR) 3 (1–5) 2 (1–4) 0.04
Haemoptysis: no. (%) 22 (27%) 35 (34%) 0.3
%Predicted FEV1: mean (SD) 63 (20) 64 (19) 0.7
St George’s Respiratory Questionnaire total score: median (IQR) 40.6 (27.2–55.8) 41.4 (23.9–57.5) 0.8
6-minute walk test: median (IQR)
Female 379 (303–425) 369 (332–410) 0.6
Male 454 (396–489) 419 (335–450) 0.04
Chest radiograph
Cavity disease: no.(%) 41/75 (55%) 47/82 (57%) 0.7
% lung affected: median (IQR) 45 (23–71) 36.5 (21–54) 0.3
X-ray score: median (IQR) 73 (29–100) 63 (36–88) 0.5
Sputum acid fast bacilli density: no.(%)
0 or Scanty 25 (30) 24 (23) 0.3
1+ 26 (31) 26 (25)
2+ 17 (20) 33 (32)
3+ 15 (18) 20 (19)
Haemoglobin (g/dL): mean (SD)
Female 10.4 (1.7) 12.1 (2.0) 0.0009
Male 11.6 (1.6) 13.6 (2.3) ,0.0001
M. tuberculosis identified from sputum at diagnosis 68/75 (91%) 88/97 (91%) 1.0
Resistant to rifampicin and isoniazid 0 2/88 (2.3%)
TB PATIENTS AT TREATMENT COMPLETION
Weight (kg): mean (SD)
All 54.4 (7.1) 52.8 (9.0) 0.3
Female 50.1 (8.4) 48.2 (10.1) 0.5
Male 56.7 (5.0) 55.1 (7.5) 0.3
Body mass index (kg/m2): mean (SD)
All 22.1 (2.8) 21.1 (3.3) 0.06
Female 21.8 (3.9) 21.2 (4.3) 0.7
Male 22.3 (2.0) 21.0 (2.6) 0.02
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a 6-minute walk test (6MWT) and a locally adapted St George’s
Respiratory Questionnaire (SGRQ, in Indonesian) were per-
formed at baseline then at 2 and 6 months. The SGRQ is a
respiratory health-related quality of life instrument, shown to be
an effective tool in measuring PTB morbidity [32,33]. Low scores
indicate better lung health. We have previously reported on the
use of the Indonesian modified SGRQ among TB patients in
Timika [33]. Chest x-rays were scored according to a previously-
reported method [34]. Pulmonary function (forced vital capacity,
FVC and forced expiratory volume in 1 second, FEV1) was
measured outdoors (for infection control purposes) using a
handheld spirometer (MicroLoopH, MicroMedical, UK), with
individual-use filtered one-way mouthpieces (Sure-GardH) suitable
for use in smear-positive PTB. Percentage of predicted FEV1 was
calculated from local normal reference ranges [35]. 6MWT was
assessed according to standard procedures [36].
Standing height was measured without shoes to the nearest
centimetre using a stadiometer; weight was measured without
shoes to the nearest 0.1 kg using an adult balance; BMI was
calculated in the standard way: weight (kg) / height (m)2. Venous
full blood count and haemoglobin concentration were measured
using a Sysmex KX-21NTM Automated Hematology Analyzer.
HIV antibody testing was as per standard local practice using a
rapid point-of-care test (Standard Diagnostics BioLine HIV-1/2
3.0TM), with positive results confirmed on 2 additional rapid tests
(Abbott DetermineTM HIV-1/2 [Inverness Medical], and Onco-
probeTM [PT Oncoprobe Utama].
Sputum microscopy was undertaken at the Timika field
laboratory weekly for 2 months then at months 5 and 6. Baseline,
1-month and 2-month sputum cultures were processed at a World
Health Organisation-accredited reference laboratory at the
University of Indonesia, Jakarta, using the BACTECH Mycobac-
terium Growth Indicator Tube (MGIT) 960 system. Sputum
culture conversion at 2 months is a standard early measure of TB
treatment response [1,2]. Sputum smear conversion was defined as
$2 consecutive negative smears without a subsequent positive.
Statistical methods
Analyses were undertaken using Stata 12.1. Proportions were
compared using Chi-squared test, or Fisher’s exact test where
necessary. Continuous variables were compared using Student’s 2-
sample T test or Wilcoxon rank sum test depending on their
distribution. Associations between sputum culture status and other
measures were tested using univariable and multivariable logistic
regression models. Multivariable models were created using a
backwards stepwise approach, including in the first model all
variables shown to be related to culture status in univariable
models (p#0.06), and variables which differed between ethnic
groups at baseline (e.g. age, HIV status). Kaplan-Meier survival
analysis was used to examine sputum smear conversion time;
patient subgroup analyses were performed by Cox regression
(proportional-hazards) models and hazard ratios and 95%
confidence intervals.
Results
Baseline study participant characteristics
One hundred and eighty six participants (83 Papuan, 103 non-
Papuan Indonesians) with PTB who met inclusion criteria were
enrolled June 2008 - November 2009 and followed up for 6
months. Participants’ characteristics showing differences between
the two ethnic groups are provided in Table 1. There were two
instances of multidrug-resistant (MDR)-TB identified, both in non-
Papuan participants. Papuans with PTB were younger than non-
Papuans, were more likely to smoke, be HIV positive, report
longer illness duration prior to diagnosis, and have lower
haemoglobin (Table 1). Papuan males had significantly higher
baseline bodyweight and BMI, and were able to walk further, than
non-Papuans. Most Papuans (82%) but less than half of the non-
Papuans (45%) had a BMI considered ‘normal’ according to the
standard definition ($18.5 mg/kg2) (Table 1; Figure 1). Similar
differences were seen in women with PTB, but their numbers were
smaller and the differences were not statistically significant. No
such differences were observed between ethnic groups in 38
healthy controls (Table 1).
Among the 18 HIV positive participants, CD4 T cell counts
were measurable in 6 individuals (median 318 cells/mL, range 18–
739), and only 2 were able to receive antiretroviral therapy during
TB treatment, one from before TB diagnosis, the other from week
20, as described elsewhere [37]. Clinical features additional to the
findings consistent with PTB included cervical lymphadenopathy
in 1 person and oro-oesoephageal candididasis in 4 people.
The TB medication dosage received by Papuans was not
statistically significantly different from that received by non-
Papuans, since most people of both ethnic groups were in the 40–
54 kg band, for whom 3 FDC tablets daily is recommended
(Table 1). There were no significant ethnic differences in
radiological severity (presence of cavitary disease, extent of lung
involvement or overall score), proportion of people with haemop-
tysis, pulmonary function, or the subjective quality of life measure
(SGRQ).
Table 1. Cont.
Papuans Non-Papuans p value
Xray score
Cavity disease: no.(%) 6/38 (15%) 8/39 (21%) 0.4
% lung affected: median (IQR) 6 (2–14) 11.5 (4–20) 0.06
X-ray score: median (IQR) 6 (2–15) 12.5 (4–20.5) 0.08
HEALTHY VOLUNTEERS: Number 19 19
Female: no. (%) 6 (32%) 3 (16%) 0.2
Weight (kg): mean (SD) 61.6 (10.4) 63.4 (9.9) 0.6
Body mass index (kg/m2): mean (SD) 24.2 (4.1) 24.4 (3.7) 0.9
doi:10.1371/journal.pone.0076077.t001
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Outcomes
As well as having greater weight and BMI at diagnosis (Table 1,
Figures 1 and 2), Papuans showed larger early increases in weight
than non-Papuans, which later plateaued (Figures 2A and B). Non-
Papuans gained weight steadily throughout treatment, such that by
treatment completion, the gap in weight between the ethnic
Figure 2. Weight according to ethnic group. A. Body weight by ethnic group at tuberculosis diagnosis and during 6 months of treatment. B.
Percentage weight change by ethnic group at tuberculosis diagnosis and during 6 months of treatment. p value for comparison between ethnic
groups shown at each time point
doi:10.1371/journal.pone.0076077.g002
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groups had closed (at 6 months, mean weight in Papuans: 54.4 kg,
versus Non-Papuans: 52.8 kg, p= 0.3). Haemoglobin was lower in
Papuans throughout the study (Table 1 and Figure 3). At
treatment completion, there was a trend toward higher chest X-
ray scores in Papuans, but the difference was not statistically
significant, and less than half the participants had a 6-month x-ray
Figure 3. Haemoglobin by ethnic group at tuberculosis diagnosis and during 6 months of treatment.
doi:10.1371/journal.pone.0076077.g003
Figure 4. Kaplan-Meier survival curve showing probability of sputum smear conversion. A. by baseline sputum smear grade. B. by
presence or absence of pulmonary cavities. C. by ethnicity. D. by BMI category.
doi:10.1371/journal.pone.0076077.g004
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reported (Table 1). Other clinical measures (pulmonary function
measures, 6MWT, SGRQ) did not differ between ethnic groups at
6 months (data not shown).
The median time to smear conversion was 5 weeks (IQR 2–8).
Baseline smear grade and cavitary status, but no other variables,
predicted time to smear conversion (Figure 4A–D).
The proportions of study participants achieving negative
sputum cultures were 62% (93/151) at 1 month and 78% (94/
120) at 2 months. Culture conversion likelihood at months 1 and 2
were closely related (p= 0.007), but determinants of culture
conversion at these time points differed. In univariable analyses,
baseline sputum smear grade, pulmonary function, total x-ray
score, presence of cavities and illness duration all predicted 1-
month culture conversion (Table 2). In multivariable analyses,
both x-ray score (p = 0.002) and sputum smear grade (p= 0.059)
remained as significant predictors (Table 2). By 2 months, baseline
sputum smear grade remained an important determinant, but
ethnicity and weight also showed significant associations with
culture conversion; ethnicity and baseline sputum AFB grade
remained significant in the multivariable model (Table 2). Culture
conversion had been achieved at 2 months by 49/56 (88%) of
Papuans, and 45/64 (70%) of non-Papuans (p = 0.02). Multi-drug
resistance was detected in only 2 people and was not significantly
associated with outcome: one patient with MDR-TB was
transferred during week 2 and hence no follow up samples were
available, and sputum culture status in the other was unavailable
at 1 month but positive at 2 months.
Seven participants were transferred elsewhere for treatment
completion. In the remaining 179, 6-month TB treatment
outcome was successful in 146 (81.6%) and unsuccessful in 33
(18.4%) (Table 3). Two people died and two failed. No significant
associations could be identified between microbiological outcomes
(4 or 8-week culture or time to microscopy conversion) or other
patient variables (e.g. ethnicity, sex, HIV or smoking status,
presence of drug resistance and presence of cavitary lung disease
on x-ray) and 6-month TB outcome category. However the 4
people who died or failed were on average 10 years older (mean
Table 2. Associations between sputum culture conversion and clinical variables in univariable and multivariable analyses (p valus
,0.05 shown in bold).
Independent variable: 1-month sputum culture Independent variable: 2-month sputum culture
(1 = positive, 0 = negative) (1 = positive, 0 = negative)
Dependent variable
Univariable odds ratio (95%
CI), p value Mulitvariable Univariable Mulitvariable
Female (vs male) 0.77 (0.37–1.60), p = 0.49 NS 1.25 (0.50–3.13), p = 0.64 NS
Age (years) 1.00 (0.97–1.03), p = 0.96 NS 1.02 (0.99–1.06), p = 0.22 NS
Weight (kg) 0.98 (0.93–1.02), p = 0.29 NS 0.93 (0.87–0.99), p=0.03 NS
Current smoker 0.47 (0.22–1.02), p = 0.06 NS 0.87 (0.33–2.30), p = 0.78 NS
Papuan (vs Non-Papuan) 1.16 (0.60–2.24), p = 0.65 NS 0.34 (0.13–0.88), p=0.03 0.36 (0.14–0.97), p=0.04
HIV+ (vs HIV-) 0.98 (0.35–2.73), p = 0.97 NS 0.24 (0.03–1.95), p = 0.18 NS
Sputum acid fast bacillus
density (grade)
1.83 (1.29–2.60), p=0.001 1.46 (0.99–2.12), p = 0.06 1.92 (1.21–3.05), p=0.005 0.87 (1.17–3.00), p=0.009
Cavitary disease 3.45 (1.64–7.26), p=0.001 NS 2.26 (0.85–6.01), p = 0.10 NS
Xray score (units) 1.02 (1.01–1.03), p,0.0001 1.02 (1.01–1.03), p=0.002 1.01 (1.00–1.02), p = 0.12 NS
FVC (L) 0.68 (0.43–1.06), p = 0.09 NS 0.96 (0.54–1.69), p = 0.88 NS
FEV1 (L) 0.57 (0.34–0.96), p=0.04 NS 0.94 (0.49–1.80), p = 0.86 NS
% Predicted FEV1 (L) 10.97 (0.96–0.99), p=0.006 NS 1.00 (0.98–1.03), p = 0.62 NS
Haemoglobin (g/dL) 0.91 (078–1.06), p = 0.22 NS 1.03 (0.80–1.33), p = 0.81 NS
White cell count 1.16 (1.04–1.30), p =0.008 NS 1.10 (0.95–1.28), p = 0.22 NS
doi:10.1371/journal.pone.0076077.t002
Table 3. Six month outcome.
Outcome N (%) Culture positive at week 4: n(%) Culture positive at week 8: n(%)
Cured 118 (63) 37/105 (35) 15/89 (17)
Completed 28 (15) 7/20 (35) 4/16 (25)
Failed 2 (1) 1/1 (100) 2/2 (100)
Defaulted 29 (16) 10/21 (48) 3/10 (30)
Died 2 (1) 1/2 (50) 0/1 (0)
Transferred 7 (4) 2/2 (100) 2/2 (100)
TOTAL 186 58 (31.2) 26 (14.0)
doi:10.1371/journal.pone.0076077.t003
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age 40.8 years) than the 146 participants with a successful outcome
(30.6 years), p = 0.08.
Discussion
We have demonstrated that TB patients of Papuan ethnicity in
eastern Indonesia are more likely to achieve sputum culture
clearance at 2 months, and maintain higher body weight despite
having similar or worse disease severity than non-Papuan
Indonesians. Weight maintenance and greater early percentage
weight gains after commencing treatment may partly explain the
early outcome advantage seen in the Papuan ethnic group. The
difference between ethnic groups decreased during the continu-
ation phase of treatment, with no difference in likelihood of
treatment success seen at 6 months, and no persisting difference in
weight at treatment completion; however, BMI remained slightly
higher among Papuan than non-Papuan males, and there was a
suggestion of possible better radiological outcomes in Papuans.
The Papuans in this study were slightly younger than non-
Papuans. Younger age (e.g. #65 versus .65 years) has been
associated with more rapid smear or culture conversion in some
studies [8,9,11]. However, age was not a significant predictor of
microbiological outcome in this study, and the association between
ethnicity and outcome remained significant when accounting for
age (Table 2).
Differences in BMI, and in the relationship between BMI and
body fat stores, are recognised in healthy populations of different
ethnicity [23–26,38]. Here the difference appears to be particu-
larly accentuated in the setting of pulmonary TB, being less
evident by treatment completion, and not present in the healthy
controls. Greater weight loss in the non-Papuans was not
attributable to greater disease severity in this group, on the basis
of radiological grade, AFB density or other measures of severity at
diagnosis. In fact taking into account HIV and smoking rates,
reported illness duration prior to treatment commencement, and
haemoglobin, Papuans might have been expected to have been
more unwell, and have lower BMI, in contrast to our findings.
The pathogenesis of weight loss in TB is multi-factorial.
Expression of tumour necrosis factor-a (TNF-a, ‘cachexin’) is an
important component of the human antimycobacterial immune
response [39], but is also thought to be responsible in part for TB-
related cachexia [40,41]. ‘Anabolic block’, whereby utilization of
amino acids for protein synthesis may be impaired by pro-
inflammatory cytokines, has also been proposed as a contributor to
TB-related weight loss [42]. Disease-related loss of appetite also
occurs. The extent of weight loss correlates with radiological
severity in TB in some studies [43]. Our findings are hypothesis-
generating: for example, it is possible that Papuans express less
TNF-a in response to TB infection, or have different dietary habits
in the context of illness. We were unable to systematically evaluate
dietary intake in all study participants prior to and during
treatment. Differences in muscle or bone mass may also
contribute, but not to a large extent, given the lesser differences
noted in weight at treatment completion or in the healthy controls.
Anti-TB medication dosing is weight-based, but higher TB drug
dosing does not appear to explain the ethnic differences, since the
recommended FDC dosing is the same between 40 and 54 kg, and
Papuans did not receive higher doses overall than non-Papuans.
The higher HIV rate in Papuans than non-Papuans in patients
included in this dataset has been reported previously [37]. The
lower haemoglobin among Papuans is likely to be due to a range of
factors and cannot be considered a reliable marker of nutritional
status in this environment: in addition to the TB-related anaemia
of chronic disease which improved with institution of TB
treatment (Figure 3), the ethnic disparity may relate to differential
rates between these groups of malaria, iron deficiency, intestinal
helminth infections or haemoglobinopathies [44]. Disparities in
haemoglobin were not related to proportions of females, which
were similar among the Papuans and non-Papuan groups in this
study (31 vs 34%, Table 1).
Limitations of the study include that additional measures of
nutritional status, such as skinfold thicknesses or dual energy X-ray
absorptiometry, were not undertaken, but these are not usually
performed as part of routine TB care, whereas weight is
universally included in the baseline and follow-up assessments of
TB patients. Our number of healthy volunteers was small, but the
trend in weight /BMI seen in TB patients during recovery
supports the findings in the healthy control group.
Our findings on the importance of baseline smear grade and
cavitary status in predicting early TB microbiological outcomes
concur with many previous studies [6,8–11]. However of note, we
also found that the predictors of TB outcome varied at different
time points. Culture conversion at 1 month was associated in
univariable analyses with measures of baseline disease severity,
whereas host factors (weight and ethnicity) appeared to become
more important by 2 months. Lack of an association between the
6-month outcome and earlier microbiological results is not
unexpected since an unsuccessful outcome (death or default)
occurred prior to being able to collect 1- or 2-month sputum
specimens in some instances, and numbers with unsuccessful
outcomes were small (Table 3). 6-month outcome categories are
appropriate for programmatic monitoring, but provide minimal
information of discriminatory value about patient clinical
outcomes. This emphasises that TB biomarkers which could
provide better measures of treatment response than standard 6-
month outcome categories are required, and that alternative
measures of illness impact are needed to assess clinically relevant
measures of TB outcome such as residual pulmonary disability
[33].
Conclusions
In conclusion, ethnicity accounts for differences in response to
tuberculosis treatment in people inhabiting the same environment
and receiving the same care through a single tuberculosis clinic.
Despite the widespread use of weight or BMI to measure
nutritional status and response to treatment in tuberculosis, this
study highlights potential flaws in comparing these measures
across ethnic groups. ‘Normal’ BMI ($18.5 kg/m2) might
underestimate disease severity in Papuans, and cut-points for
BMI categories should be considered as a guide only. When
interpreting the results of TB research in which absolute or
percentage changes in weight are measured, the potential for
intrinsic differences between ethnic groups needs to be acknowl-
edged.
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